Saturday, 31 October 2026European Markets

WAGA ENERGY Stock Bullish By 20% In The Last 10 Sessions

Loading stream...

(vianews) - shares of waga energy (cac 40: waga.pa) rose by a staggering 20.91% in 10 sessions from €22 to €26.60 at 17:05 est on friday, after two successive sessions in a row of gains. cac 40 is sliding 0% to €7,222.32, following the last session's upward trend.

about waga energy

waga energy société anonyme, together with its subsidiaries, develops biomethane injections projects serving the energy transitions. it is involved in the design, development, financing, construction, installation, and exploitation solutions, as well as sale of biomethane. the company was incorporated in 2015 and is headquartered in meylan, france.

earnings per share

as for profitability, waga energy has a trailing twelve months eps of €-0.51.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, waga energy's stock is considered to be oversold (<=20).

volatility

waga energy's last week, last month's, and last quarter's current intraday variation average was 0.45%, 0.97%, and 2.92%.

waga energy's highest amplitude of average volatility was 0.95% (last week), 2.85% (last month), and 2.92% (last quarter).

volume

today's last reported volume for waga energy is 1953 which is 75.16% below its average volume of 5713.

more news about waga energy (waga.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com